Neurogene (NGNE) vs Puma Biotechnology (PBYI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Puma Biotechnology (PBYI) has outperformed Neurogene (NGNE) over the past year, gaining 97.5% versus a gain of 2.6%. Over five years, PBYI leads with a +70.1% price change compared with -81.6% for NGNE. Puma Biotechnology is the larger company by market cap ($531.2 million vs $528.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NGNE | PBYI |
|---|---|---|
| Share price | $26.40 | $10.29 |
| Market cap | $528.30M | $531.17M |
| 1-day change | -0.38% | +3.21% |
| YTD return | +28.64% | +72.94% |
| 1-year return | +2.59% | +97.50% |
| 5-year return | -81.65% | +70.08% |
| P/E ratio (TTM) | — | 20.18 |
| Forward P/E | — | 29.40 |
| EPS (TTM) | $-5.04 | $0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.66 | $10.35 |
| 52-week low | $15.93 | $4.58 |
| Distance from 52-week high | -39.53% | -0.58% |
| Analyst consensus | none | none |
| Avg. price target upside | +195.00% | — |
| Average volume | 247.13K | 320.69K |
| Shares outstanding | 20.01M | 51.62M |
| Employees | 131 | 179 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PBYI has outperformed NGNE by 94.9 percentage points over the past year.
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
About Puma Biotechnology
PBYI stock →Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees
NGNE vs PBYI FAQ
Which is bigger, Neurogene or Puma Biotechnology?
Puma Biotechnology (PBYI) is larger, with a market capitalization of $531.17M compared with $528.30M for Neurogene (NGNE).
Which stock has performed better over the past year, NGNE or PBYI?
PBYI returned +97.50% over the past 12 months, compared with +2.59% for NGNE (price return, excluding dividends). Past performance does not predict future results.
Are Neurogene and Puma Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.